Company name
Athebio AG
Company profile
- Athebio is a bootstrapped biotech founded in 2019, headquartered in Bio-Techpark Schlieren-Zürich
- Athebio developed an ultra-stable Athebody® DARPin to enable novel targeted biotherapeutic approaches
- Strategic partnerships for targeted radio-therapy (with Eli Lilly/Point) and targeted LNP (with Acuitas) established
- Seeking funding for Newco to develop game changing biotherapeutics for GI related diseases (IBD), by direct targeting of gut epithelium and tissue
Date, time and room information
Tuesday, May 5, 14:45 - 15:00, room Singapore
Category
Emerging biotech company
Title of the presentation
Ultra-st able biotherapeutics for precision targeting
Speaker information
| Name | Position | Institution |
|---|---|---|
| Thomas Huber | CEO |
